Nafithromycin WCK 4873 » National Chronicle

Wockhardt completes Phase 3 pneumonia study of its macrolide antibiotic Nafithromycin WCK 4873

April 18, 2024December 11, 2023 by Team NC

Wockhardt has announced the completion of the pivotal Phase 3 pneumonia Study of its macrolide antibiotic Nafithromycin WCK 4873.